source
- Sickle cell gene-editing therapy shows signs of revival as developers revisit trial after earlier safety haltA recent STAT+ article highlights that a sickle cell gene‑editing therapy, whose trial was stopped three years ago after a serious adverse event in the first patient, may be making a comeback. The…
- RevMed stock rises on early Rasonque sales as whistleblower sues Madrigal over MASH safetyRevMed announced its first sales figures for Rasonque, a therapy targeting pancreatic cancer, and the news sent the company's shares higher. The company said the early sales data reflect market up…